Key facts
- Loberamisil, a drug developed in China, has shown it can extend the treatment window for stroke patients.
- The drug extends the window from six hours to 48 hours.
- This extension could significantly improve outcomes for stroke patients by allowing more time for intervention.
A drug developed in China, Loberamisil, has demonstrated the potential to significantly broaden the time frame for treating stroke patients. Previously, the effective treatment window for acute ischemic stroke was limited to six hours. However, Loberamisil has shown in studies that it can extend this critical period to 48 hours. This advancement could lead to improved patient outcomes by providing medical professionals with a much larger window to administer necessary treatments and interventions.